MOBIDIAG
2.6.2020 06:02:06 CEST | Business Wire | Press release
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address infectious diseases, antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received CE-IVD markings for its Novodiag® COVID-19 and Amplidiag® COVID-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19).
These tests complement the Company’s already available antibody test, Anti-SARS-CoV-2 Rapid Test , that Mobidiag is distributing from its joint venture partner in China, Autobio Diagnostics. Mobidiag is now able to commercially offer a comprehensive diagnostic solution for novel coronavirus infections for hospital and lab based settings.
Due to the high demand for diagnostic devices and tests globally, Mobidiag has ensured that its supply chain and manufacturing capabilities are robust and able to support its customers. This includes, for example, the sourcing and acquisition of various consumables to cover the complete workflow from sample collection to the results (e.g. inhouse production of enzymes and the development of our proprietary mNAT™ Medium sample buffer and collection tubes).
Tuomas Tenkanen, CEO of Mobidiag, said, “With the CE-IVD mark approvals for our Novodiag COVID-19 and Amplidiag COVID-19 molecular diagnostic tests and our distribution of the Anti-SARS-CoV-2 Rapid antibody test, Mobidiag is now able to provide a complete diagnostic solution for the detection of COVID-19 infections across the life cycle of the virus.”
“Mobidiag has leveraged its existing technologies and expertise, including supply chain management and manufacturing, to ensure we are able to deliver a full range of diagnostic solutions to our customers.”
The Novodiag® COVID-19 and Amplidiag® COVID-19 molecular diagnostic tests are able to rapidly and reliably detect COVID-19 infections at an early stage in patients with signs and symptoms of respiratory infection. They have already earlier been granted emergency use authorisation in Finland, Sweden and France. The tests have been designed using dual targets of SARS-CoV-2 (orf1ab & N genes) to include at least one conserved region and one specific region to mitigate the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses.
The Novodiag® COVID-19 assay allows qualitative determination of SARS-CoV-2 (orf1ab and N genes) directly from nasopharyngeal swabs. The test operates using the Novodiag® rapid ‘sample-in, result-out’ system, allowing the on demand fully automated detection of COVID-19 in approximately 1 hour. In addition, Novodiag® solution is a closed system which ensures the protection of laboratory staff and healthcare professionals from possible contamination. The user-friendly nature of the system means that the Novodiag® system can also be used in high risk and hard-to-reach areas and decentralized settings without the need for highly trained personnel.
The Amplidiag® COVID-19 assay complements the Novodiag® COVID-19 on demand test. Based on well-established high-throughput qualitative PCR technology, 48 samples can be processed in less than three hours while running on Mobidiag’s Amplidiag® Easy platform , which enables to clinicians an optimized sample screening process with automated DNA/RNA extraction and PCR plate setup.
In addition to these molecular tests, Mobidiag is distributing an antibody test allowing qualitative determination of Anti-SARS-CoV-2 (IgG and IgM antibodies of SARS-CoV-2) in human serum, plasma or whole blood in less than 15 minutes without any instrumentation. The Anti-SARS-CoV-2 Rapid Test is manufactured by Mobidiag’s joint venture partner in China, Autobio Diagnostics.
Please note that these tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Please follow the recommended processes and guidance for your location if you believe you could be infected by SARS-CoV-2.
Notes to editors
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200601005614/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
i2c Marks a Year of Momentum Driving Financial Institutions and Fintechs in the Race to Modernize21.10.2026 15:00:00 CEST | Press release
New client wins, expanded partnerships, and a wave of industry recognition reflect growing demand for i2c and its PowerOne platform i2c Inc., a global financial technology innovator, today recapped key milestones from the past year as financial institutions and fintechs raced to modernize their banking and payments technology. Behind that race is mounting pressure. New American Banker research in partnership with i2c found that 88% of financial institutions have accelerated their modernization timelines due to competition from digital-first banks, fintechs, and non-bank providers, with executives most often citing legacy processing architecture as the greatest barrier. Too many remain stuck choosing between legacy platforms with proven scale and modern platforms with agility. For more than 26 years, i2c has helped clients skip that trade-off entirely. i2c’s next-gen PowerOne unified banking and payments platform gives clients one global foundation to outperform competitors running on f
Civil Air Patrol Orders 21 New Cessna Aircraft to Strengthen Lifesaving and Community Missions21.10.2026 15:00:00 CEST | Press release
New Skyhawk, Skylane and Stationair aircraft will support CAP missions across the U.S., with deliveries anticipated in 2027 Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an order from Civil Air Patrol (CAP) for 21 additional Cessna piston aircraft that will support CAP's emergency response, training and community missions across the U.S. Deliveries are expected to be completed in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021955281/en/ Maj. Gen. Regena Aye and Brig. Gen. R. Jason Bailey of the Civil Air Patrol tour Cessna piston assembly at Textron Aviation’s facility in Independence, Kansas The order includes seven Cessna Skyhawk 172 aircraft, 11 Cessna Skylane 182 aircraft, two Cessna Turbo Skylane T182T aircraft and one Cessna Turbo Stationair HD 206 aircraft. CAP is the world's largest operator of Cessna aircraft. “These Cessna aircraft help ensure our members are ready when comm
Klarna Launches Consumer FX: Shop From Klarna Merchants Worldwide, Regardless of Currency21.10.2026 14:47:00 CEST | Press release
Klarna Group Plc (NYSE: KLAR), the everyday finance network, today launched Consumer FX, which allows shoppers to buy from any participating Klarna merchant in the world and pay in their own currency, with no exchange fee. The price and rate are shown upfront and stay visible in the Klarna app after purchase, so there are no surprises on the statement. The new launch means any Klarna connected merchant can sell to Klarna’s 120 million consumers in 26 countries with no new integration, and no need for a local entity of foreign bank account. Klarna also handles FX disclosure, consent and compliance. Early results show merchants gain a 5% lift in conversion and 6% in sales due to the expanded reach. The launch comes as cross-border payments are growing globally. DHL reports that 70% of 2026 shoppers buy internationally, up 10% from 2025, and 45% buy across borders more than once a month.1 “Increasingly, shoppers aren’t thinking in borders,” says David Sykes, Chief Commercial Officer, Klar
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors21.10.2026 14:35:00 CEST | Press release
Collaboration to explore how AI-facilitated technology can help make patient support programs more individualized, responsive and continuously available to people living with rare tumorsCollaboration brings together clinical and pharmaceutical expertise, digital health product development, and enterprise AI servicesMerck aims to bring the model to patients with desmoid tumors and neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) Merck, a leading science and technology company, today announced a collaboration with NVIDIA Corporation (Santa Clara, California, USA), Microsoft Corporation (Redmond, Washington, USA) and Dawn Health A/S (Copenhagen, Denmark) to build an innovative model for Patient Support Programs (PSPs). The four-way collaboration brings together pharmaceutical and clinical expertise, enterprise technology, AI services and digital health product design, with the shared goal of making specialist-level support more individualized, responsive and continuously ava
Corpay Cross-Border Named the Official FX Partner of Newcastle United21.10.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into a multi-year agreement with Newcastle United to become their Official Foreign Exchange (FX) Partner. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Newcastle United’s day-to-day business operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “We’re thrilled to be named the Official FX Partner of Newcastle United, one of the Premier League’s most iconic and ambitious clubs,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership further strengthens Corpay’s position as the trusted corporate payments and currency risk management provider of choice across the Premier League. We loo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom